Bimekizumab

MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update

Retrieved on: 
Tuesday, May 7, 2024
Komodo, Psoriatic arthritis, VELA, FDA, American Academy, Porokeratosis, Psoriasis, HS, Skin, Rheumatology, MDA, Research, Partnership, Conference, PPP, MIRA, Joint, Bimekizumab, Patient, EMA, AAD, Inflammation, PASI, Moonlake, Dermatology, ARGO, Pharmaceutical industry

Dr. Jorge Santos da Silva, Chief Executive Officer of MoonLake Immunotherapeutics, said: “2024 is shaping up to be a strong year for MoonLake.

Key Points: 
  • Dr. Jorge Santos da Silva, Chief Executive Officer of MoonLake Immunotherapeutics, said: “2024 is shaping up to be a strong year for MoonLake.
  • Research and development expenses for the quarter ended March 31, 2024, were $13.0 million, compared to $8.1 million in the previous quarter.
  • The increase was primarily due to expenses incurred to initiate the new clinical trials.
  • General and administrative expenses for the quarter ended March 31, 2024 were $6.8 million, similar to the $6.9 million incurred in the previous quarter.

BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

Retrieved on: 
Wednesday, October 18, 2023
Science, Patient, FDA, UCB, National Psoriasis Foundation, Psoriasis, Week, Icahn School of Medicine at Mount Sinai, Plaque, Food, Observational study, MD, Information, Skin, Cytokine, BE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Bimekizumab, Jeff Flake, Mount Sinai, Adalimumab, Ustekinumab, Safety, Therapy, Pharmaceutical industry, Medical imaging, Dermatology, Medicine

"With BIMZELX now approved for psoriasis, we will move forward rapidly to submit applications for additional indications in the U.S."

Key Points: 
  • "With BIMZELX now approved for psoriasis, we will move forward rapidly to submit applications for additional indications in the U.S."
    "We have been eagerly awaiting bimekizumab, the first IL-17A and IL-17F inhibitor, to be approved in the U.S. for the treatment of adults with moderate-to-severe plaque psoriasis.
  • "The approval of bimekizumab will provide an important new treatment option for adults living with moderate-to-severe plaque psoriasis," said Leah McCormick Howard, J.D., President and CEO for the National Psoriasis Foundation.
  • "Our hope is that new treatments translate into improved outcomes for many and help alleviate the physical and emotional burden of psoriasis."
  • For additional medical information, patient assistance or any other information, please call UCBCares® at 1-844-599-CARE (2273) or visit askucbcares.com .

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

Retrieved on: 
Friday, October 13, 2023
Diagnosis, Food, Abstract, Research, UCB, Report of the 1st Annual Symposium on Relaxed Improvisation, Insurance, Safety, Bimekizumab, Hidradenitis suppurativa, Policy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BE, Pharmaceutical industry, Pain, Patient, Political moderate, HS

ATLANTA, Oct. 13, 2023 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that it will present six abstracts in hidradenitis suppurativa (HS) at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA), October 13–15 in Phoenix, Arizona.

Key Points: 
  • ATLANTA, Oct. 13, 2023 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that it will present six abstracts in hidradenitis suppurativa (HS) at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA), October 13–15 in Phoenix, Arizona.
  • "The data to be presented at SHSA reinforce our commitment to advancing medicines in areas where patients have the greatest need," said Emmanuel Caeymaex, Executive Vice President, Immunology Solutions and Head of U.S., UCB.
  • In a second oral presentation, 48-week data evaluating the impact of bimekizumab on health-related quality of life will be shared.
  • Three poster presentations will include subgroup analyses from the two Phase 3 studies, including 48-week data in U.S. patients.

Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

Retrieved on: 
Thursday, October 12, 2023
Congress, Journal of the European Academy of Dermatology and Venereology, Food, Hidradenitis, UCB, Week, Safety, Classification, Patient, IL-17A, Immunology, Maintenance, Abscess, II, Hidradenitis suppurativa, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Coronavirus, BE, Body mass index, HS, Medical imaging, Pharmaceutical industry, Nursing, Fertilizer, Dermatology, Venereology, Bimekizumab, Allergy

There is a compelling need for new treatment options that can offer high and durable clinical response," said Emmanuel Caeymaex, Executive Vice President, Immunology Solutions and Head of U.S., UCB.

Key Points: 
  • There is a compelling need for new treatment options that can offer high and durable clinical response," said Emmanuel Caeymaex, Executive Vice President, Immunology Solutions and Head of U.S., UCB.
  • "Data presented at EADV showed that over 48 weeks many patients treated with bimekizumab achieved high thresholds of response.
  • These findings suggest that inhibition of IL-17F in addition to IL-17A represents a promising treatment approach in moderate-to-severe hidradenitis suppurativa."
  • "The bimekizumab Phase 3 clinical trial program in hidradenitis suppurativa included the more stringent clinical outcomes of HiSCR75, HiSCR90 and HiSCR100 in addition to the standard HiSCR50.

Novel biologic Ab-IPL-IL-17™ shows promise for rheumatoid arthritis and inflammatory bowel disease

Retrieved on: 
Tuesday, August 15, 2023
RA, University, Rheumatology, Annals of the Rheumatic Diseases, University of Naples Federico II, IBD, Arthritis, Research, Multimedia, Inflammation, Bimekizumab, Protein, Psoriasis, Immunotherapy, Inflammatory bowel disease, Patent, Patient, Blood, University of Birmingham, Immune-mediated inflammatory diseases, Ixekizumab, Lymphocyte, Rheumatoid arthritis, Pharmaceutical industry, Vaccine, Medical device, Frankincense

The antibody, called Ab-IPL-IL-17™, targets a specific section of signalling proteins IL-17A and IL-17F which play a central role in sustaining inflammation during onset and progression of autoimmune diseases.

Key Points: 
  • The antibody, called Ab-IPL-IL-17™, targets a specific section of signalling proteins IL-17A and IL-17F which play a central role in sustaining inflammation during onset and progression of autoimmune diseases.
  • A patent application has been filed covering the antibody and its therapeutic use.
  • The researchers are seeking commercial partners willing to conduct a large-scale clinical evaluation of Ab-IPL-IL17™ in patients with immune-mediated inflammatory diseases (IMIDs).
  • For commercial enquiries contact Dr Veemal Bhowruth at University of Birmingham Enterprise.

Novel biologic Ab-IPL-IL-17™ shows promise for rheumatoid arthritis and inflammatory bowel disease

Retrieved on: 
Tuesday, August 15, 2023
RA, University, Rheumatology, Annals of the Rheumatic Diseases, University of Naples Federico II, IBD, Arthritis, Research, Inflammation, Bimekizumab, Protein, Psoriasis, Immunotherapy, Inflammatory bowel disease, Patent, Patient, Blood, University of Birmingham, Immune-mediated inflammatory diseases, Ixekizumab, Lymphocyte, Rheumatoid arthritis, Pharmaceutical industry, Vaccine, Medical device

The antibody, called Ab-IPL-IL-17™, targets a specific section of signalling proteins IL-17A and IL-17F which play a central role in sustaining inflammation during onset and progression of autoimmune diseases.

Key Points: 
  • The antibody, called Ab-IPL-IL-17™, targets a specific section of signalling proteins IL-17A and IL-17F which play a central role in sustaining inflammation during onset and progression of autoimmune diseases.
  • A patent application has been filed covering the antibody and its therapeutic use.
  • The researchers are seeking commercial partners willing to conduct a large-scale clinical evaluation of Ab-IPL-IL17™ in patients with immune-mediated inflammatory diseases (IMIDs).
  • For commercial enquiries contact Dr Veemal Bhowruth at University of Birmingham Enterprise.

Hidradenitis Suppurativa Global Market to 2030: Increased Disposable Income Fuels the Sector - ResearchAndMarkets.com

Retrieved on: 
Monday, May 1, 2023
Health, Pharmaceutical, AbbVie, Pfizer, Obesity, UCB, Patient, Hidradenitis suppurativa, Eli Lilly and Company, Rollcage Stage II, Smoking, Skin, Pharmaceutical industry, Bimekizumab

By Region: The report provides insight into the global hidradenitis suppurativa market based on the geographical operations, namely the US, Europe and Rest of the World.

Key Points: 
  • By Region: The report provides insight into the global hidradenitis suppurativa market based on the geographical operations, namely the US, Europe and Rest of the World.
  • The US dominates the hidradenitis suppurativa market because of the surging adoption of newer techniques in this region.
  • By Patient: According to the report, the US hidradenitis suppurativa market is segmented into the patients with Stage II and Stage III hidradenitis suppurativa.
  • Obesity, smoking, and a sedentary lifestyle in the US would lead to an increase in Stage II and Stage III hidradenitis suppurativa patients.

MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update

Retrieved on: 
Monday, March 20, 2023
Secukinumab, Skin, Therapy, TNF, Psoriatic arthritis, Capital market, Event, Medical college, Clinical trial, Psoriasis, American Academy, EST, Research, Inflammation, IL-17A, Antibody, Bimekizumab, AAD, Patient, Data, Rheumatology, Medical College of Wisconsin, Webcast, Moonlake, Phase, News, Safety, Security (finance), Pharmaceutical industry, Cryptocurrency, Dermatology, HS

Dr. Jorge Santos da Silva, Chief Executive Officer of MoonLake Immunotherapeutics, said: “2022 was an excellent year for MoonLake.

Key Points: 
  • Dr. Jorge Santos da Silva, Chief Executive Officer of MoonLake Immunotherapeutics, said: “2022 was an excellent year for MoonLake.
  • 2023 looks even more important with results from our two global trials expected during the year.
  • Research and development expenses for the fourth quarter ended December 31, 2022 were $11.4 million, compared to $9.0 million in the previous quarter.
  • General and administrative expenses for the fourth quarter ended December 31, 2022 were $5.3 million, compared to $5.7 million in the previous quarter.

UCB to Present Eight Bimekizumab Abstracts at AAD 2023 with Results from Studies in Psoriasis, Psoriatic Arthritis, and Hidradenitis Suppurativa

Retrieved on: 
Thursday, March 16, 2023
Abstract, Psoriatic arthritis, Bimekizumab, Secukinumab, Psoriasis, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Skin, BE, Maintenance, AAD, UCB, American Academy, Patient, Conditional sentence, Psoriasis Area and Severity Index, Welsh Terrier, HS, Hidradenitis suppurativa, Week, Safety, Food, American Academy of Dermatology, Phase 3, Pharmaceutical industry, Medical imaging

The abstracts have been accepted as one late-breaking oral platform presentation and seven posters, including three with oral presentations.

Key Points: 
  • The abstracts have been accepted as one late-breaking oral platform presentation and seven posters, including three with oral presentations.
  • Five of the eight abstracts at AAD 2023 will share data on bimekizumab in the treatment of moderate to severe plaque psoriasis, including data evaluating bimekizumab in the treatment of nail psoriasis from the BE RADIANT Phase 3b trial.
  • Bimekizumab versus secukinumab for the treatment of nail psoriasis in patients with moderate to severe plaque psoriasis: Results from the BE RADIANT phase 3b trial.
  • Bimekizumab improved efficacy measures in patients with active psoriatic arthritis and moderate or severe psoriasis: Pooled 16-week results from phase 3 randomized, placebo-controlled studies BE OPTIMAL and BE COMPLETE.

2022 Worldwide Psoriatic Arthritis Treatment Industry Epidemiology & Pipeline Analysis Report - by Drug Class, Gender Type, Disease Type, Age Group, Severity Type and Geography - ResearchAndMarkets.com

Retrieved on: 
Monday, November 28, 2022
Health, Pharmaceutical, Psoriatic arthritis, III, Union, TNF, Trauma, Risk, Pain, Ustekinumab, Risk factor, Safety, Patient, Arthritis, Disease, Nail disease, Therapy, Psoriasis, Ageing, Clinical trial, Woman, Obesity, Pharmaceutical industry, Tildrakizumab, Bimekizumab, Phase, Epidemiology

The "Psoriatic Arthritis Treatment Market Forecast - Epidemiology & Pipeline Analysis 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Psoriatic Arthritis Treatment Market Forecast - Epidemiology & Pipeline Analysis 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory rheumatic disease characterized by pain, stiffness, swollen joints, joint erosion, and bone formation.
  • Psoriatic arthritis occurs in up to 30% of patients with psoriasis, most commonly those aged between 30 and 60 years.
  • In recent years, women have contributed more to the global psoriatic arthritis treatment market as they are at greater risk of developing psoriatic arthritis.